久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

Amsbio
公司位于美國(guó)加州，1987年成立于西班牙，歷經(jīng)多年的變動(dòng)與改革，已成為多樣化實(shí)驗(yàn)室試劑的供應(yīng)商；并在全世界建立完整的銷售網(wǎng)，提供各地區(qū)的實(shí)驗(yàn)室完善的銷售服務(wù)。
AMS為基因組學(xué)，蛋白質(zhì)組學(xué)和免疫學(xué)提供研究產(chǎn)品。產(chǎn)品包括檢測(cè)套組，基因，核糖核酸，蛋白質(zhì)芯片，免疫印跡，多克隆抗體，單克隆抗體，抗原與試劑。

AMSBIO’s mission is to be a profitable premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. This is achieved by offering small and medium size manufacturers, academic groups and revenue generating biotechs a unique partnership for the global market and by providing state of the art and cost effective solutions to end users and partners.


Company History
Formed in 1987 by Sandy Allan and Alex Sim the company’s first offices were in Madrid, Spain. Over the following three years further offices were opened in Italy, Switzerland and the UK. During the formative years of existence AMS helped launch the successful sales campaigns of Stratagene and Invitrogen providing them with an important foothold from which to develop their global brand expansion.

AMSBIO partnered with Pharmingen and contributed to their development until 1996 when they were sold to Becton Dickenson.

In 1995 AMSBIO raised investment capital from 3i and other private sources to support the expansion of the European network to Germany and Sweden and to launch one of the first real time quantitative PCR platforms.

In 1997 the company restructured resulting in the departure of Sandy Allan. The instrumentation division was closed and subsidiaries in Sweden, Italy and Spain were sold. The development of the ImmunoKontact (IK) brand continued with licensing agreements with Novartis the Basel Institute of Immunology and a number of academic institutes.

Concurrently with the development of IK, AMSBIO partnered with Ambion driving European sales forward 10 fold in only three years. Through a strategic arrangement, the company assisted in the formation of Ambion Europe which eventually would lead to Ambion being sold to Applied Biosystems.


AMSBIO serves the European market from facilities in Switzerland, Germany and the UK. This latter location provides the logistics and distribution services as well as housing a multi lingual marketing and technical staff made up of scientists with many years of experience in cutting edge technology.

In 2003 AMSBIO set up facilities for producing peptides and providing hybridoma and monoclonal services. Initially called ABE and based in Switzerland these facilities have expanded to include laboratory locations in Southern California and Oxfordshire. Custom services include monoclonal antibody production, custom protein expression and polyclonal antibody services. In 2010 AMSBIO added stable cell line production and lentivirus technology for shRNA and overexpression needs.

Ambitious companies serving the global research science market need state of the art solutions to be able to generate success and help establish a critical mass. The current amsbio portfolio is a testimony to this. Specializing in Genomics, Proteomics, Cell Culture and Stem Cell Sciences, AMSBIO continues to offer a wide range of solutions from leading manufacturing partners and academic technology transfer departments. Key areas include cell migration, invasion, adhesion and proliferation where a number of platforms suitable for high content analysis are available. Growing cells in 3D is physiologically relevant and the most innovative set of products and technology currently commercially available for 3-D cell culture has been put together under the AMSBIO umbrella. These products are being used in key regenerative medicine therapy and cancer research as well as offering alternatives to the use of animals in biomedical research.

AMS Biotechnology’s biorespository offers the biggest range of tissue products from a single source. RNA, DNA, protein and tissue sections and arrays are available from diseased and normal sources and multiple donor provision and prospective collection is also possible.

During 2009 3i sold its investment in AMSBIO to Alex Sim, the group’s interests are now represented in AMSBIO holdings. AMSBIO LLC was formed in 2011 to take control of Southern California based laboratory and physical distribution assets.

The global customer base continues to grow significantly and AMS Biotechnology ships to most countries where life science research is being carried out. Key brands include Zymolyase, Cellufine, Cultrex, alvetex, RNAbee and RNAStat all are now also available to US customers from AMSBIO LLC.

Seikagaku recently announced their withdrawal from the reagents and biotools market. AMSBIO has invested significantly in this sector by purchasing inventory from Japan and also developing similar products in the Glycobiology space. Please check out www.proteoglycan.info for the ongoing developments and launch of new products.

A long term objective of AMSBIO is to reduce its carbon footprint and to maximize the recycling of materials. In 2008 a significant reduction in the use of polystyrene boxes, the use of dry ice and the minimizing of multiple shipments was made through the investment in state of the art facilities in Southern California and Oxfordshire, UK. These facilities consolidate shipping from and to multiple locations in the US and Europe and have lead AMSBIO to its first step in constructing its global green bio-bridge.

AMSBIO through its ImmunoKontact activities will continue to develop custom services. Recently DNA damage screening, Cell based assays, Tumour Xenograft, and stem cell culture have been added to the expanding menu.